Limitations of Applying the Hematopoietic Cell Transplantation Comorbidity Index in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation

Allogeneic HCT (alloHCT) is a curative treatment option for many children with malignant and non-malignant diseases [1 –9]. However, alloHCT is associated with the risk of significant toxicities that can result in substantial morbidity and mortality. Identifying which patients are at high risk for transplant related mortality, prior to alloHCT, is crucial both to guide decision-making with patients and families an d to inform the alloHCT approach.

Source: Biology of Blood and Marrow Transplantation - October 7, 2020 Category: Hematology Authors: Larisa Broglie, Jenny Ruiz, Zhezhen Jin, Justine M. Kahn, Monica Bhatia, Diane George, James Garvin, Prakash Satwani Source Type: research